Sundar Jagannath, MD, chief of the Multiple Myeloma and Transplant program at SVCCC, presented Role of Bortezomib in Myeloma Patients Eligible for High-Dose Therapy, at the 2007 Kos conference. For an abstract of the presentation>>

–>

If you are a person living with a rare cancer, or a parent of a child with a rare cancer, this article will provide tips and resources to help you obtain information about your specific diagnosis and treatment options. There are a variety of resources available that can provide credible information and support. Read the full article, with links to resources>>

–>

Michael P. Fanucchi, MD, medical director, and Sundar Jagannath, MD, chief of the Multiple Myeloma and Transplant Program, SVCCC, will co-present at the February 22-23, 2008, Sixth International Symposium on Evolution of Supportive Care in Oncology: The Era of Targeted Agents, held in New York City. Their topic will be Management of Adverse Events with Proteosome Inhibitors.

The annual meeting focuses on supportive treatments to manage unique class effect toxicities of novel biologic agents that are currently being incorporated in the treatment regimens of malignancies and discusses chemotherapy-induced conditions. The format of the symposium includes didactic lectures, debates on optimal therapeutic approaches, and interactive case-based discussions, question and answer sessions. For more information about the symposium>>

–>

CancerCare’s E-News for July offers lots of free patient-oriented booklets and advice for patients: Side Effect Management, The Future Role of Cancer Vaccines, Understanding and Managing Chemotherapy Side Effects, Finding New Ways to Cope with Fatigue, and others. To access CancerCare E-News>>

–>